Gastroenterology & Hepatology Clinical Trials

Statistical methods in gastroenterology & hepatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All gastroenterology & hepatology trials

476 results

• CHALLENGEIndependent statistical analysis of Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer: primary endpoint results, effect estimate…Phase NAResults postedn = 889NCT00819208
• CheckMate 8HWIndependent statistical analysis of A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC):…Phase 3Results postedn = 839NCT04008030
• Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia: Complete Statistical AnalysisIndependent statistical analysis of Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 41NCT00503776
• Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 4NCT01285102
• Chemoprevention of Gastric Carcinogenesis: Complete Statistical AnalysisIndependent statistical analysis of Chemoprevention of Gastric Carcinogenesis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02794428).Phase 2Results postedn = 91NCT02794428
• Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00176800).Phase 2Results postedn = 69NCT00176800
• Chemoradiation in Locally Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemoradiation in Locally Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00262951).Phase 2Results postedn = 23NCT00262951
• Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 252NCT00094809
• Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 62NCT00393068
• Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 11NCT01959672
• Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery: Complete Statistical AnalysisIndependent statistical analysis of Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2/3Results postedn = 635NCT04068103
• CJC-TraCIndependent statistical analysis of Criminal Justice Coordinated Transitional Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05376371).Phase NAResults postedn = 219NCT05376371
• Clinical Studies on Bile Acids in Barrett’s Esophagus: Complete Statistical AnalysisIndependent statistical analysis of Clinical Studies on Bile Acids in Barrett's Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00858858).Phase NAResults postedn = 60NCT00858858
• Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 94NCT00291668
• Clinical Study to Evaluate CryoBalloon™ Full and Swipe Ablation Systems for Ablation of Human Esophageal Epithelium: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study to Evaluate CryoBalloon™ Full and Swipe Ablation Systems for Ablation of Human Esophageal Epithelium: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 10NCT02729753
• Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection: Complete Statistical AnalysisIndependent statistical analysis of Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 135NCT01596283
• ColdPlay2Independent statistical analysis of Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Epithelium: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 58NCT02534233
• Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis: Complete Statistical AnalysisIndependent statistical analysis of Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01066364).Phase 2Results postedn = 59NCT01066364
• Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2/3Results postedn = 36NCT00227617
• Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 124NCT00982592
• Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia: Complete Statistical AnalysisIndependent statistical analysis of Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 47NCT03734822
• Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin: Complete Statistical AnalysisIndependent statistical analysis of Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 427NCT01069939
• Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection: Complete Statistical AnalysisIndependent statistical analysis of Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 69NCT00096785
• Compare Propofol to Fentanyl and Midazolam for Colonoscopy: Complete Statistical AnalysisIndependent statistical analysis of Compare Propofol to Fentanyl and Midazolam for Colonoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01488045).Phase NAResults postedn = 289NCT01488045
• Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 126NCT03288987
• Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation: Complete Statistical AnalysisIndependent statistical analysis of Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation: primary endpoint results, effect estimate…Phase 1Results postedn = 9NCT07093008
• Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery: Complete Statistical AnalysisIndependent statistical analysis of Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in…Phase 3Results postedn = 19NCT04588246
• Comparison of a Novel 22-gauge Core Biopsy Needle: Complete Statistical AnalysisIndependent statistical analysis of Comparison of a Novel 22-gauge Core Biopsy Needle: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01598194).Phase NAResults postedn = 60NCT01598194
• Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings: Complete Statistical AnalysisIndependent statistical analysis of Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 4Results postedn = 17NCT00685035
• Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals: Complete Statistical AnalysisIndependent statistical analysis of Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 602NCT02933970
• Comparison of the Efficacy of a Biological Implant to Reinforce Overlapping Sphincter Repair Versus Overlapping Sphincter Repair Alone: Complete Statistical AnalysisIndependent statistical analysis of Comparison of the Efficacy of a Biological Implant to Reinforce Overlapping Sphincter Repair Versus Overlapping Sphincter Repair Alone: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 13NCT01044589
• Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis: Complete Statistical AnalysisIndependent statistical analysis of Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01173159).Phase NAResults postedn = 10NCT01173159
• Conditionally Increased Output (CIO) Enhanced Ultrasound System: Complete Statistical AnalysisIndependent statistical analysis of Conditionally Increased Output (CIO) Enhanced Ultrasound System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05792423).Phase NAResults postedn = 24NCT05792423
• CONFLICTIndependent statistical analysis of A Study of the Quality of Life in Adults With Crohn's Disease With Complex Perianal Fistulas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 15NCT04876690
• Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 37NCT03648879
• Contrast-enhanced Ultrasound Evaluation of Chemoembolization: Complete Statistical AnalysisIndependent statistical analysis of Contrast-enhanced Ultrasound Evaluation of Chemoembolization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02764801).Phase 3Results postedn = 131NCT02764801
• Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 24NCT02631590
• COSMOSIndependent statistical analysis of A Study in Participants With Non-cirrhotic NASH With Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05638737).Phase 2Results postedn = 112NCT05638737
• CTS-1027 in Interferon-Naive Hepatitis C Patients: Complete Statistical AnalysisIndependent statistical analysis of CTS-1027 in Interferon-Naive Hepatitis C Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00925990).Phase 2Results postedn = 70NCT00925990
• CTSI-PLACEIndependent statistical analysis of A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 87NCT02597790
• CYTOFLOCIndependent statistical analysis of Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03529669).Phase NAResults postedn = 41NCT03529669
• DAHHS-2Independent statistical analysis of Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 80NCT02600325
• Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 87NCT00966277
• DARE-CIndependent statistical analysis of DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01743521).Phase 4Results postedn = 14NCT01743521
• Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00504153).Phase 2Results postedn = 19NCT00504153
• DEARIndependent statistical analysis of Dose Escalation and Remission (DEAR): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00652145).Phase 4Results postedn = 119NCT00652145
• Design and Implementation of a Nutritional Intervention in Patients With Oropharyngeal Dysphagia: Complete Statistical AnalysisIndependent statistical analysis of Design and Implementation of a Nutritional Intervention in Patients With Oropharyngeal Dysphagia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 127NCT02959450
• Detection of Barrett s Esophagus in Patients Without GERD Symptoms: Complete Statistical AnalysisIndependent statistical analysis of Detection of Barrett s Esophagus in Patients Without GERD Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04880044).Phase NAResults postedn = 132NCT04880044
• Diagnosis of Acute Appendicitis: Low-dose Computed Tomography (CT) Versus Standard-dose CT: Complete Statistical AnalysisIndependent statistical analysis of Diagnosis of Acute Appendicitis: Low-dose Computed Tomography (CT) Versus Standard-dose CT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 891NCT00913380
• DietGERDIndependent statistical analysis of Dietary Carbohydrate and GERD in Veterans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02384551).Phase NAResults postedn = 150NCT02384551

← All therapeutic areas